Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
    May 2024
  1. ADLER AI, Coleman RL, Leal J, Whiteley WN, et al
    Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
    Lancet. 2024 May 17:S0140-6736(24)00537-3. doi: 10.1016/S0140-6736(24)00537.
    >> Share

    March 2024
  2. BROWN DM, Boyer DS, Do DV, Wykoff CC, et al
    Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
    Lancet. 2024 Mar 7:S0140-6736(23)02577-1. doi: 10.1016/S0140-6736(23)02577.
    >> Share

  3. GABRIELLE PH, Creuzot-Garcher C
    Can high-dose aflibercept satisfy unmet treatment needs in diabetic macular oedema?
    Lancet. 2024 Mar 7:S0140-6736(23)02760-5. doi: 10.1016/S0140-6736(23)02760.
    >> Share

    January 2024
    Treating obesity and diabetes: drugs alone are not enough.
    Lancet. 2024;403:1.
    >> Share

    November 2023
  5. HEERSPINK HJL, Kiyosue A, Wheeler DC, Lin M, et al
    Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
    Lancet. 2023 Nov 2:S0140-6736(23)02230-4. doi: 10.1016/S0140-6736(23)02230.
    >> Share

  6. ZHAO X, Duaso M, Ghazaleh HA, Cheng L, et al
    Effectiveness of interventions for improving physical activity level in working-age people (aged 18-60 years) with type 2 diabetes: a systematic review and meta-analysis.
    Lancet. 2023;402 Suppl 1:S97.
    >> Share

  7. SPENCER LH, Albustami M, Porter A, Naha G, et al
    Uptake of diabetes follow-up checks by minority community groups: a rapid review of the evidence for the CYMELL study.
    Lancet. 2023;402 Suppl 1:S86.
    >> Share

  8. EVANS J, White P, Ha H
    Evaluating the effectiveness of community health worker interventions on glycaemic control in type 2 diabetes: a systematic review and meta-analysis.
    Lancet. 2023;402 Suppl 1:S40.
    >> Share

  9. BOZKURT D, Duaso M, Sturt J
    Use of the 2021 UK Medical Research Council guidance to refine the Women's Wellness with Type 2 Diabetes Programme: a mixed-methods study.
    Lancet. 2023;402 Suppl 1:S27.
    >> Share

  10. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    >> Share

  11. PIDD K, Breeze P, Pollard D, Ahern A, et al
    Estimation of HbA(1c) after weight loss using a beta-regression for an economic evaluation of a behavioural weight management programme from the GLoW trial: a methodological study.
    Lancet. 2023;402 Suppl 1:S75.
    >> Share

  12. GEDEON E, Henderson M, Leyland AH, Allik M, et al
    Association between care experience and mental health hospitalisation among children in Scotland, with a focus on chronic conditions (CHiCS): a population-wide longitudinal study using administrative data.
    Lancet. 2023;402 Suppl 1:S5.
    >> Share

  13. AYOUB A, Akyea RK, L'Esperance V, Ayis S, et al
    Determinants of lipid clinic referral and attendance in a multi-ethnic adult population in south London: a cross-sectional study.
    Lancet. 2023;402 Suppl 1:S26.
    >> Share

    October 2023
  14. HINKLE SN, Mumford SL, Grantz KL, Mendola P, et al
    Gestational weight change in a diverse pregnancy cohort and mortality over 50 years: a prospective observational cohort study.
    Lancet. 2023 Oct 19:S0140-6736(23)01517-9. doi: 10.1016/S0140-6736(23)01517.
    >> Share

  15. RUSSELL-JONES D, Babazono T, Cailleteau R, Engberg S, et al
    Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
    Lancet. 2023 Oct 17:S0140-6736(23)02179-7. doi: 10.1016/S0140-6736(23)02179.
    >> Share

  16. SHAH AS, Wolf RM
    Weekly insulin: a paradigm shift in type 1 diabetes therapy.
    Lancet. 2023 Oct 17:S0140-6736(23)02227-4. doi: 10.1016/S0140-6736(23)02227.
    >> Share

  17. KIVUYO S, Birungi J, Okebe J, Wang D, et al
    Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial.
    Lancet. 2023;402:1241-1250.
    >> Share

  18. KISIGO GA, Peck RN
    Integrating HIV, hypertension, and diabetes primary care in Africa.
    Lancet. 2023;402:1211-1213.
    >> Share

    August 2023
  19. NAUCK MA, Horowitz M
    Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists.
    Lancet. 2023;402:429-431.
    >> Share

    June 2023
  20. ROSENSTOCK J, Frias J, Jastreboff AM, Du Y, et al
    Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Lancet. 2023 Jun 26:S0140-6736(23)01053-X. doi: 10.1016/S0140-6736(23)01053.
    >> Share

  21. BAIN SC, Min T
    A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena.
    Lancet. 2023 Jun 26:S0140-6736(23)01182-0. doi: 10.1016/S0140-6736(23)01182.
    >> Share

  22. GARVEY WT, Frias JP, Jastreboff AM, le Roux CW, et al
    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi: 10.1016/S0140-6736(23)01200.
    >> Share

  23. FRANDSEN CS, Madsbad S
    SURMOUNT-2: new advances for treating obese type 2 diabetes with tirzepatide.
    Lancet. 2023 Jun 26:S0140-6736(23)01292-8. doi: 10.1016/S0140-6736(23)01292.
    >> Share

    Diabetes: a defining disease of the 21st century.
    Lancet. 2023;401:2087.
    >> Share

  25. FRIAS JP, Hsia S, Eyde S, Liu R, et al
    Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
    Lancet. 2023 Jun 23:S0140-6736(23)01302-8. doi: 10.1016/S0140-6736(23)01302.
    >> Share

  26. APOVIAN CM, McDonnell ME
    CagriSema and the link between obesity and type 2 diabetes.
    Lancet. 2023 Jun 23:S0140-6736(23)01291-6. doi: 10.1016/S0140-6736(23)01291.
    >> Share

  27. FRIAS JP, Deenadayalan S, Erichsen L, Knop FK, et al
    Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
    Lancet. 2023 Jun 23:S0140-6736(23)01163-7. doi: 10.1016/S0140-6736(23)01163.
    >> Share

  28. ARODA VR, Aberle J, Bardtrum L, Christiansen E, et al
    Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
    Lancet. 2023 Jun 23:S0140-6736(23)01127-3. doi: 10.1016/S0140-6736(23)01127.
    >> Share

  29. SHERRILL CH, Hwang AY
    The pursuit of optimal semaglutide dosing in type 2 diabetes continues.
    Lancet. 2023 Jun 23:S0140-6736(23)01233-3. doi: 10.1016/S0140-6736(23)01233.
    >> Share

  30. KNOP FK, Aroda VR, do Vale RD, Holst-Hansen T, et al
    Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 23:S0140-6736(23)01185-6. doi: 10.1016/S0140-6736(23)01185.
    >> Share

  31. WATKINS DA, Ali MK
    Measuring the global burden of diabetes: implications for health policy, practice, and research.
    Lancet. 2023 Jun 22:S0140-6736(23)01287-4. doi: 10.1016/S0140-6736(23)01287.
    >> Share

  32. WALKER AF, Graham S, Maple-Brown L, Egede LE, et al
    Interventions to address global inequity in diabetes: international progress.
    Lancet. 2023 Jun 22:S0140-6736(23)00914-5. doi: 10.1016/S0140-6736(23)00914.
    >> Share

  33. AGARWAL S, Wade AN, Mbanya JC, Yajnik C, et al
    The role of structural racism and geographical inequity in diabetes outcomes.
    Lancet. 2023 Jun 22:S0140-6736(23)00909-1. doi: 10.1016/S0140-6736(23)00909.
    >> Share

  34. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2023 Jun 22:S0140-6736(23)01301-6. doi: 10.1016/S0140-6736(23)01301.
    >> Share

  35. DAVIES MJ, Ahmad E, Lim S, Lamptey R, et al
    Cancer is becoming the leading cause of death in diabetes - Authors' reply.
    Lancet. 2023;401:1849-1850.
    >> Share

  36. WANG M, Sperrin M, Rutter MK, Renehan AG, et al
    Cancer is becoming the leading cause of death in diabetes.
    Lancet. 2023;401:1849.
    >> Share

    May 2023
  37. MATHIEU C, Asbjornsdottir B, Bajaj HS, Lane W, et al
    Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
    Lancet. 2023 May 5:S0140-6736(23)00520-2. doi: 10.1016/S0140-6736(23)00520.
    >> Share

  38. CONRAD N, Misra S, Verbakel JY, Verbeke G, et al
    Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.
    Lancet. 2023 May 5:S0140-6736(23)00457-9. doi: 10.1016/S0140-6736(23)00457.
    >> Share

    April 2023
  39. VERRASTRO O, Panunzi S, Castagneto-Gissey L, De Gaetano A, et al
    Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00634-7. doi: 10.1016/S0140-6736(23)00634.
    >> Share

  40. QUATTRIN T, Mastrandrea LD, Walker LSK
    Type 1 diabetes.
    Lancet. 2023 Apr 5:S0140-6736(23)00223-4. doi: 10.1016/S0140-6736(23)00223.
    >> Share

    March 2023
  41. GREGG EW, Buckley J, Ali MK, Davies J, et al
    Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact.
    Lancet. 2023 Mar 14:S0140-6736(23)00001-6. doi: 10.1016/S0140-6736(23)00001.
    >> Share

    February 2023
  42. PERDOMO CM, Cohen RV, Sumithran P, Clement K, et al
    Contemporary medical, device, and surgical therapies for obesity in adults.
    Lancet. 2023 Feb 9:S0140-6736(22)02403-5. doi: 10.1016/S0140-6736(22)02403.
    >> Share

    November 2022
  43. BURKI T
    HPV and diabetes researchers win Prince Mahidol Awards.
    Lancet. 2022;400:1837-1838.
    >> Share

  44. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02074.
    >> Share

  45. AHMAD E, Lim S, Lamptey R, Webb DR, et al
    Type 2 diabetes.
    Lancet. 2022 Nov 1. pii: S0140-6736(22)01655.
    >> Share

  46. BUSH KJ, Papacosta AO, Lennon L, Rankin J, et al
    The influence of neighbourhood-level socioeconomic deprivation on developing type 2 diabetes in older men: a longitudinal analysis of the British Regional Heart Study cohort data.
    Lancet. 2022;400 Suppl 1:S26.
    >> Share

    October 2022
  47. URVA S, Coskun T, Loh MT, Du Y, et al
    LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
    Lancet. 2022 Oct 27. pii: S0140-6736(22)02033.
    >> Share

  48. MYERS B, Lombard CJ, Lund C, Joska JA, et al
    Comparing dedicated and designated approaches to integrating task-shared psychological interventions into chronic disease care in South Africa: a three-arm, cluster randomised, multicentre, open-label trial.
    Lancet. 2022;400:1321-1333.
    >> Share

    August 2022
  49. CONRAD N, Verbeke G, Molenberghs G, Goetschalckx L, et al
    Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01349.
    >> Share

  50. VADUGANATHAN M, Docherty KF, Claggett BL, Jhund PS, et al
    SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01429.
    >> Share

  51. TUTTLE KR, Rangaswami J
    SGLT2 inhibitors as the bedrock of therapy for heart failure.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01584.
    >> Share

  52. TESFAYE S, Sloan G, Petrie J, White D, et al
    Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, rando
    Lancet. 2022 Aug 22. pii: S0140-6736(22)01472.
    >> Share

    June 2022
  53. GOLUBIC R, Barber TM, Caleyachetty R
    Obesity definition for personalised treatment of type 2 diabetes.
    Lancet. 2022;399:2189.
    >> Share

  54. LINGVAY I, Sumithran P, Cohen RV, Roux CWL, et al
    Obesity definition for personalised treatment of type 2 diabetes Authors' reply.
    Lancet. 2022;399:2189-2190.
    >> Share

    May 2022
  55. DASHRAATH P, Chen K, Htet ZW, Chan SY, et al
    Pre-eclampsia with paradoxical polyuria: diabetes insipidus in pregnancy.
    Lancet. 2022;399:1809.
    >> Share

    March 2022
  56. ALESSI J, Yankiv M
    War in Ukraine and barriers to diabetes care.
    Lancet. 2022 Mar 21. pii: S0140-6736(22)00480.
    >> Share

    February 2022
  57. WATTS G
    Viroj Tangcharoensathien: master carpenter of Thai health care.
    Lancet. 2022;399:e9.
    >> Share

    Diabetes and race in the USA over the past century.
    Lancet. 2022;399:712-713.
    >> Share

    January 2022
  59. WYKOFF CC, Abreu F, Adamis AP, Basu K, et al
    Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
    Lancet. 2022 Jan 21. pii: S0140-6736(22)00018.
    >> Share

    November 2021
  60. BHUTTA ZA, Salam RA, Gomber A, Lewis-Watts L, et al
    A century past the discovery of insulin: global progress and challenges for type 1 diabetes among children and adolescents in low-income and middle-income countries.
    Lancet. 2021;398:1837-1850.
    >> Share

  61. NAZARZADEH M, Bidel Z, Canoy D, Copland E, et al
    Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.
    Lancet. 2021;398:1803-1810.
    >> Share

    Monica Peek: addressing diabetes health disparities.
    Lancet. 2021;398:1792.
    >> Share

  63. CAVENDER MA, Wirka RC
    Blood pressure lowering in the prevention of type 2 diabetes.
    Lancet. 2021;398:1778-1779.
    >> Share

  64. HELLER SR, Durrant A, Tandon N
    Insulin, the patient, and the health professional.
    Lancet. 2021;398:1785-1786.
    >> Share

    100 years of insulin: a technical success but an access failure.
    Lancet. 2021;398:1777.
    >> Share

  66. DEVI S
    Cold comfort: getting insulin to those who need it.
    Lancet. 2021;398:1791.
    >> Share

    October 2021
  67. KHOO B, Tan TM
    Surpassing insulin glargine in type 2 diabetes with tirzepatide.
    Lancet. 2021 Oct 18. pii: S0140-6736(21)02279.
    >> Share

  68. DEL PRATO S, Kahn SE, Pavo I, Weerakkody GJ, et al
    Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    Lancet. 2021 Oct 18. pii: S0140-6736(21)02188.
    >> Share

    September 2021
  69. LINGVAY I, Sumithran P, Cohen RV, le Roux CW, et al
    Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation.
    Lancet. 2021 Sep 30. pii: S0140-6736(21)01919.
    >> Share

    June 2021
  70. NORGAARD K, Schmidt S
    Is reimbursement for alerts and real-time continuous glucose monitoring needed?
    Lancet. 2021;397:2230-2232.
    >> Share

    April 2021
  71. POWELL EE, Wong VW, Rinella M
    Non-alcoholic fatty liver disease.
    Lancet. 2021 Apr 21. pii: S0140-6736(20)32511.
    >> Share

    March 2021
  72. FIGTREE GA, Vernon ST, Hadziosmanovic N, Sundstrom J, et al
    Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Lancet. 2021;397:1085-1094.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016